{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T23:08:12Z","timestamp":1769814492547,"version":"3.49.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82473378"],"award-info":[{"award-number":["82473378"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Shanghai Pulmonary Hospital Research-Oriented Physician Talent Program","award":["LYRC202407"],"award-info":[{"award-number":["LYRC202407"]}]},{"name":"Tongji University Medicine-X Interdisciplinary Research Initiative","award":["TJ-FK-YXJC022"],"award-info":[{"award-number":["TJ-FK-YXJC022"]}]},{"name":"Shanghai Talents Development Fund Project","award":["2021071"],"award-info":[{"award-number":["2021071"]}]},{"name":"Shanghai Municipal Health Commission Seed Funding Program for Research and Translation of New Medical Technologies","award":["2025ZZ2011"],"award-info":[{"award-number":["2025ZZ2011"]}]},{"name":"Clinical Research Foundation of Shanghai Pulmonary Hospital","award":["SKPY2021006"],"award-info":[{"award-number":["SKPY2021006"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s11060-025-05374-6","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T10:23:38Z","timestamp":1766053418000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combined stereotactic radiotherapy and immunotherapy improves survival in driver-gene-negative NSCLC patients with brain oligo-metastases: a multicenter real-world study"],"prefix":"10.1007","volume":"176","author":[{"given":"Shilan","family":"Luo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rufei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongbin","family":"Tu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuangqing","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingdan","family":"Pang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Litang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3043-9562","authenticated-orcid":false,"given":"Xiaomei","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"5374_CR1","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.ejca.2020.03.006","volume":"132","author":"S Page","year":"2020","unstructured":"Page S, Milner-Watts C, Perna M, Janzic U, Vidal N, Kaudeer N et al (2020) Systemic treatment of brain metastases in non-small cell lung cancer. Eur J Cancer 132:187\u2013198. https:\/\/doi.org\/10.1016\/j.ejca.2020.03.006","journal-title":"Eur J Cancer"},{"issue":"4","key":"5374_CR2","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1001\/jama.2016.9839","volume":"316","author":"PD Brown","year":"2016","unstructured":"Brown PD, Jaeckle K, Ballman KV, Farace E, Cerhan JH, Anderson SK et al (2016) Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: A randomized clinical trial. JAMA 316(4):401\u2013409. https:\/\/doi.org\/10.1001\/jama.2016.9839","journal-title":"JAMA"},{"key":"5374_CR3","doi-asserted-by":"publisher","unstructured":"Chen Y-H, Ho U-C, Kuo L-T (2022) Oligometastatic disease in non-small-cell lung cancer: an update. Cancers (Basel) 14(5). https:\/\/doi.org\/10.3390\/cancers14051350","DOI":"10.3390\/cancers14051350"},{"issue":"21","key":"5374_CR4","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1001\/jama.295.21.2483","volume":"295","author":"H Aoyama","year":"2006","unstructured":"Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K et al (2006) Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 295(21):2483\u20132491","journal-title":"JAMA"},{"key":"5374_CR5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.lungcan.2016.04.004","volume":"96","author":"F Hsu","year":"2016","unstructured":"Hsu F, De Caluwe A, Anderson D, Nichol A, Toriumi T, Ho C (2016) EGFR mutation status on brain metastases from non-small cell lung cancer. Lung Cancer (Amsterdam Netherlands) 96:101\u2013107. https:\/\/doi.org\/10.1016\/j.lungcan.2016.04.004","journal-title":"Lung Cancer (Amsterdam Netherlands)"},{"issue":"4","key":"5374_CR6","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1007\/s10147-014-0760-9","volume":"20","author":"T Iuchi","year":"2015","unstructured":"Iuchi T, Shingyoji M, Itakura M, Yokoi S, Moriya Y, Tamura H et al (2015) Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations. Int J Clin Oncol 20(4):674\u2013679. https:\/\/doi.org\/10.1007\/s10147-014-0760-9","journal-title":"Int J Clin Oncol"},{"issue":"19","key":"5374_CR7","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A et al (2016) Pembrolizumab versus chemotherapy for PD-L1-Positive Non-Small-Cell lung cancer. N Engl J Med 375(19):1823\u20131833","journal-title":"N Engl J Med"},{"issue":"17","key":"5374_CR8","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE et al (2015) Nivolumab versus docetaxel in advanced nonsquamous Non-Small-Cell lung cancer. N Engl J Med 373(17):1627\u20131639. https:\/\/doi.org\/10.1056\/NEJMoa1507643","journal-title":"N Engl J Med"},{"issue":"10066","key":"5374_CR9","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","volume":"389","author":"A Rittmeyer","year":"2017","unstructured":"Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J et al (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389(10066):255\u2013265. https:\/\/doi.org\/10.1016\/S0140-6736(16)32517-X","journal-title":"Lancet"},{"issue":"2","key":"5374_CR10","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, Crin\u00f2 L, Eberhardt WEE, Poddubskaya E et al (2015) Nivolumab versus docetaxel in advanced Squamous-Cell Non-Small-Cell lung cancer. N Engl J Med 373(2):123\u2013135. https:\/\/doi.org\/10.1056\/NEJMoa1504627","journal-title":"N Engl J Med"},{"key":"5374_CR11","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ejca.2019.09.011","volume":"123","author":"F Grossi","year":"2019","unstructured":"Grossi F, Genova C, Crin\u00f2 L, Delmonte A, Turci D, Signorelli D et al (2019) Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer. Eur J Cancer 123:72\u201380. https:\/\/doi.org\/10.1016\/j.ejca.2019.09.011","journal-title":"Eur J Cancer"},{"issue":"11","key":"5374_CR12","doi-asserted-by":"publisher","first-page":"e1165","DOI":"10.1634\/theoncologist.2018-0737","volume":"24","author":"L Crin\u00f2","year":"2019","unstructured":"Crin\u00f2 L, Bidoli P, Delmonte A, Grossi F, De Marinis F, Ardizzoni A et al (2019) Italian cohort of nivolumab expanded access program in squamous Non-Small cell lung cancer: results from a Real-World population. Oncologist 24(11):e1165\u2013e71. https:\/\/doi.org\/10.1634\/theoncologist.2018-0737","journal-title":"Oncologist"},{"issue":"5","key":"5374_CR13","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S2213-2600(20)30391-X","volume":"9","author":"WSME Theelen","year":"2021","unstructured":"Theelen WSME, Chen D, Verma V, Hobbs BP, Peulen HMU, Aerts JGJV et al (2021) Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir Med 9(5):467\u2013475. https:\/\/doi.org\/10.1016\/S2213-2600(20)30391-X","journal-title":"Lancet Respir Med"},{"issue":"7","key":"5374_CR14","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S1470-2045(17)30380-7","volume":"18","author":"N Shaverdian","year":"2017","unstructured":"Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC et al (2017) Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol 18(7):895\u2013903. https:\/\/doi.org\/10.1016\/S1470-2045(17)30380-7","journal-title":"Lancet Oncol"},{"issue":"5","key":"5374_CR15","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S1470-2045(20)30111-X","volume":"21","author":"SB Goldberg","year":"2020","unstructured":"Goldberg SB, Schalper KA, Gettinger SN, Mahajan A, Herbst RS, Chiang AC et al (2020) Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. Lancet Oncol 21(5):655\u2013663. https:\/\/doi.org\/10.1016\/S1470-2045(20)30111-X","journal-title":"Lancet Oncol"},{"key":"5374_CR16","doi-asserted-by":"publisher","unstructured":"Sun L, Davis CW, Hwang W-T, Jeffries S, Sulyok LF, Marmarelis ME et al (2021) Outcomes in patients with non-small-cell lung cancer with brain metastases treated with Pembrolizumab-based therapy. Clin Lung Cancer 22(1). https:\/\/doi.org\/10.1016\/j.cllc.2020.10.017","DOI":"10.1016\/j.cllc.2020.10.017"},{"issue":"4","key":"5374_CR17","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.jtho.2018.01.012","volume":"13","author":"HG Hubbeling","year":"2018","unstructured":"Hubbeling HG, Schapira EF, Horick NK, Goodwin KEH, Lin JJ, Oh KS et al (2018) Safety of combined PD-1 pathway Inhibition and intracranial radiation therapy in non-small cell lung cancer. J Thorac Oncol 13(4):550\u2013558. https:\/\/doi.org\/10.1016\/j.jtho.2018.01.012","journal-title":"J Thorac Oncol"},{"key":"5374_CR18","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.radonc.2020.05.038","volume":"150","author":"R Mir","year":"2020","unstructured":"Mir R, Kelly SM, Xiao Y, Moore A, Clark CH, Clementel E et al (2020) Organ at risk delineation for radiation therapy clinical trials: global harmonization group consensus guidelines. Radiother Oncol 150:30\u201339. https:\/\/doi.org\/10.1016\/j.radonc.2020.05.038","journal-title":"Radiother Oncol"},{"issue":"6","key":"5374_CR19","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1016\/S1470-2045(15)70057-4","volume":"16","author":"NU Lin","year":"2015","unstructured":"Lin NU, Lee EQ, Aoyama H, Barani IJ, Barboriak DP, Baumert BG et al (2015) Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol 16(6):e270\u2013e8. https:\/\/doi.org\/10.1016\/S1470-2045(15)70057-4","journal-title":"Lancet Oncol"},{"key":"5374_CR20","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1748-717X-6-48","volume":"6","author":"G Minniti","year":"2011","unstructured":"Minniti G, Clarke E, Lanzetta G, Osti MF, Trasimeni G, Bozzao A et al (2011) Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis. Radiat Oncol 6:48. https:\/\/doi.org\/10.1186\/1748-717X-6-48","journal-title":"Radiat Oncol"},{"issue":"1","key":"5374_CR21","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, Viera A (2021) Using the common terminology criteria for adverse events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr (Engl Ed) 112(1):90\u201392. https:\/\/doi.org\/10.1016\/j.ad.2019.05.009","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"issue":"13","key":"5374_CR22","doi-asserted-by":"publisher","first-page":"e498","DOI":"10.1016\/S1470-2045(15)00007-8","volume":"16","author":"AB Sharabi","year":"2015","unstructured":"Sharabi AB, Lim M, DeWeese TL, Drake CG (2015) Radiation and checkpoint Blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol 16(13):e498\u2013e509. https:\/\/doi.org\/10.1016\/S1470-2045(15)00007-8","journal-title":"Lancet Oncol"},{"issue":"2","key":"5374_CR23","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.ijrobp.2015.01.004","volume":"92","author":"AP Kiess","year":"2015","unstructured":"Kiess AP, Wolchok JD, Barker CA, Postow MA, Tabar V, Huse JT et al (2015) Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys 92(2):368\u2013375. https:\/\/doi.org\/10.1016\/j.ijrobp.2015.01.004","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"19","key":"5374_CR24","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1002\/cncr.30138","volume":"122","author":"JM Qian","year":"2016","unstructured":"Qian JM, Yu JB, Kluger HM, Chiang VLS (2016) Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery. Cancer 122(19):3051\u20133058. https:\/\/doi.org\/10.1002\/cncr.30138","journal-title":"Cancer"},{"issue":"2","key":"5374_CR25","doi-asserted-by":"publisher","first-page":"512","DOI":"10.3171\/2018.10.JNS181371","volume":"132","author":"C Singh","year":"2019","unstructured":"Singh C, Qian JM, Yu JB, Chiang VL (2019) Local tumor response and survival outcomes after combined stereotactic radiosurgery and immunotherapy in non-small cell lung cancer with brain metastases. J Neurosurg 132(2):512\u2013517. https:\/\/doi.org\/10.3171\/2018.10.JNS181371","journal-title":"J Neurosurg"},{"key":"5374_CR26","doi-asserted-by":"publisher","unstructured":"Shepard MJ, Xu Z, Donahue J, Eluvathingal Muttikkal TJ, Cordeiro D, Hansen L et al (2019) Stereotactic radiosurgery with and without checkpoint Inhibition for patients with metastatic non-small cell lung cancer to the brain: a matched cohort study. J Neurosurg 1\u20138. https:\/\/doi.org\/10.3171\/2019.4.JNS19822","DOI":"10.3171\/2019.4.JNS19822"},{"issue":"4","key":"5374_CR27","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.ijrobp.2017.11.041","volume":"100","author":"L Chen","year":"2018","unstructured":"Chen L, Douglass J, Kleinberg L, Ye X, Marciscano AE, Forde PM et al (2018) Concurrent immune checkpoint inhibitors and stereotactic radiosurgery for brain metastases in Non-Small cell lung Cancer, Melanoma, and renal cell carcinoma. Int J Radiat Oncol Biol Phys 100(4):916\u2013925. https:\/\/doi.org\/10.1016\/j.ijrobp.2017.11.041","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5374_CR28","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.radonc.2018.08.025","volume":"130","author":"EJ Lehrer","year":"2019","unstructured":"Lehrer EJ, Peterson J, Brown PD, Sheehan JP, Qui\u00f1ones-Hinojosa A, Zaorsky NG et al (2019) Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: an international meta-analysis of individual patient data. Radiother Oncol 130:104\u2013112. https:\/\/doi.org\/10.1016\/j.radonc.2018.08.025","journal-title":"Radiother Oncol"},{"issue":"21","key":"5374_CR29","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP et al (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372(21):2018\u20132028. https:\/\/doi.org\/10.1056\/NEJMoa1501824","journal-title":"N Engl J Med"},{"issue":"22","key":"5374_CR30","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1200\/JCO.2017.72.5952","volume":"35","author":"PA Ott","year":"2017","unstructured":"Ott PA, Bang Y-J, Berton-Rigaud D, Elez E, Pishvaian MJ, Rugo HS et al (2017) Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-Positive endometrial cancer: results from the KEYNOTE-028 study. J Clin Oncol 35(22):2535\u20132541. https:\/\/doi.org\/10.1200\/JCO.2017.72.5952","journal-title":"J Clin Oncol"},{"issue":"7","key":"5374_CR31","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s40262-019-00748-2","volume":"58","author":"M Centanni","year":"2019","unstructured":"Centanni M, Moes DJAR, Troc\u00f3niz IF, Ciccolini J, van Hasselt JGC (2019) Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors. Clin Pharmacokinet 58(7):835\u2013857. https:\/\/doi.org\/10.1007\/s40262-019-00748-2","journal-title":"Clin Pharmacokinet"},{"key":"5374_CR32","doi-asserted-by":"publisher","unstructured":"Trapani S, Manicone M, Sikokis A, D\u2019Abbiero N, Salaroli F, Ceccon G et al (2019) Effectiveness and safety of real concurrent stereotactic radiotherapy and immunotherapy in metastatic solid tumors: a systematic review. Crit Rev Oncol Hematol 142. https:\/\/doi.org\/10.1016\/j.critrevonc.2019.07.006","DOI":"10.1016\/j.critrevonc.2019.07.006"},{"key":"5374_CR33","doi-asserted-by":"publisher","unstructured":"ProcureurA,Simonaggio A, Bibault J-E, Oudard S, Vano Y-A (2021) Enhance the immune checkpoint inhibitors efficacy with radiotherapy induced Immunogenic cell death: a comprehensive review and latest developments. Cancers (Basel) 142:15-21. https:\/\/doi.org\/10.3390\/cancers13040678","DOI":"10.3390\/cancers13040678"},{"key":"5374_CR34","doi-asserted-by":"publisher","first-page":"1432281","DOI":"10.3389\/fimmu.2024.1432281","volume":"15","author":"H Wang","year":"2024","unstructured":"Wang H, Chen J, Gao W, Wu Y, Wang X, Lin F et al (2024) Construction of a nomogram with irae and clinic character to predict the survival of advanced G\/GEJ adenocarcinoma patients undergoing anti-PD-1 treatment. Front Immunol 15:1432281. https:\/\/doi.org\/10.3389\/fimmu.2024.1432281","journal-title":"Front Immunol"},{"key":"5374_CR35","doi-asserted-by":"publisher","first-page":"101959","DOI":"10.1016\/j.eucr.2021.101959","volume":"41","author":"Y Horibe","year":"2022","unstructured":"Horibe Y, Nakata W, Tsujimura G, Tsujimoto Y, Gotoh T, Tsujihata M (2022) A case of long-term complete remission of locally advanced T4 bladder cancer treated with pembrolizumab. Urol Case Rep 41:101959. https:\/\/doi.org\/10.1016\/j.eucr.2021.101959","journal-title":"Urol Case Rep"},{"issue":"6","key":"5374_CR36","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/s41416-019-0541-3","volume":"121","author":"K Yoneda","year":"2019","unstructured":"Yoneda K, Kuwata T, Kanayama M, Mori M, Kawanami T, Yatera K et al (2019) Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer. Br J Cancer 121(6):490\u2013496. https:\/\/doi.org\/10.1038\/s41416-019-0541-3","journal-title":"Br J Cancer"},{"key":"5374_CR37","doi-asserted-by":"publisher","unstructured":"Sun L, Kienzler JC, Reynoso JG, Lee A, Shiuan E, Li S et al (2023) Immune checkpoint blockade induces distinct alterations in the microenvironments of primary and metastatic brain tumors. J Clin Invest 133(17). https:\/\/doi.org\/10.1172\/JCI169314","DOI":"10.1172\/JCI169314"},{"issue":"24","key":"5374_CR38","doi-asserted-by":"publisher","first-page":"5274","DOI":"10.1002\/cncr.33196","volume":"126","author":"JM Qian","year":"2020","unstructured":"Qian JM, Martin AM, Martin K, Hammoudeh L, Catalano PJ, Hodi FS et al (2020) Response rate and local recurrence after concurrent immune checkpoint therapy and radiotherapy for non-small cell lung cancer and melanoma brain metastases. Cancer 126(24):5274\u20135282. https:\/\/doi.org\/10.1002\/cncr.33196","journal-title":"Cancer"},{"issue":"2","key":"5374_CR39","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.ijrobp.2010.05.033","volume":"81","author":"Y-J Kim","year":"2010","unstructured":"Kim Y-J, Cho KH, Kim J-Y, Lim YK, Min HS, Lee SH et al (2010) Single-dose versus fractionated stereotactic radiotherapy for brain metastases. Int J Radiat Oncol Biol Phys 81(2):483\u2013489. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.05.033","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"5374_CR40","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.ijrobp.2016.03.013","volume":"95","author":"G Minniti","year":"2016","unstructured":"Minniti G, Scaringi C, Paolini S, Lanzetta G, Romano A, Cicone F et al (2016) Single-Fraction Versus Multifraction (3 \u00d7 9 Gy) Stereotactic Radiosurgery for Large (>\u20092\u00a0cm) Brain Metastases: A Comparative Analysis of Local Control and Risk of Radiation-Induced Brain Necrosis. Int J Radiat Oncol Biol Phys 95(4):1142\u20131148. https:\/\/doi.org\/10.1016\/j.ijrobp.2016.03.013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"5374_CR41","doi-asserted-by":"publisher","first-page":"4114","DOI":"10.1007\/s00330-020-07514-0","volume":"31","author":"PH Kim","year":"2021","unstructured":"Kim PH, Suh CH, Kim HS, Kim KW, Kim DY, Aizer AA et al (2021) Immune checkpoint inhibitor therapy May increase the incidence of treatment-related necrosis after stereotactic radiosurgery for brain metastases: a systematic review and meta-analysis. Eur Radiol 31(6):4114\u20134129. https:\/\/doi.org\/10.1007\/s00330-020-07514-0","journal-title":"Eur Radiol"},{"issue":"8","key":"5374_CR42","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1001\/jamaoncol.2017.3993","volume":"4","author":"AM Martin","year":"2018","unstructured":"Martin AM, Cagney DN, Catalano PJ, Alexander BM, Redig AJ, Schoenfeld JD et al (2018) Immunotherapy and symptomatic radiation necrosis in patients with brain metastases treated with stereotactic radiation. JAMA Oncol 4(8):1123\u20131124. https:\/\/doi.org\/10.1001\/jamaoncol.2017.3993","journal-title":"JAMA Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05374-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-025-05374-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05374-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T11:47:21Z","timestamp":1769773641000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-025-05374-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["5374"],"URL":"https:\/\/doi.org\/10.1007\/s11060-025-05374-6","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"assertion":[{"value":"30 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. This study was carried out in accordance with the principles of the Declaration of Helsinki and was approved by Shanghai Pulmonary Hospital Institutional Review Board (IRB) Committee. This research study was conducted retrospectively from data obtained for clinical purposes. We consulted extensively with the IRB of Shanghai Pulmonary Hospital who determined that our study did not need informed consent. An IRB official waiver of informed consent was granted from the IRB of Shanghai Pulmonary Hospital (K21-251Z-1).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"127"}}